Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRANS_A3
- Development stage
- Preclinical
- Lead developer
- YnnoMed
- Modality
- Small Molecules
01
Overview
TRANS_A3 is a preclinical-stage small molecule antibiotic candidate being developed by YnnoMed. Developed using YnnoMed's proprietary AI-assisted drug discovery platform, the compound is designed to target essential bacterial transcription machinery. Specifically, it acts as a bacterial transcription inhibitor, disrupting protein-protein interactions involved in bacterial RNA synthesis to combat drug-resistant bacterial infections.
02
Targets
RNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on TRANS_A3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRANS_A3.